Nikita Shah Amneal Pharmaceuticals, Inc. (AMRX) insider trading activity

Nikita Shah is Executive Vice President of Amneal Pharmaceuticals, Inc.. Currently has a direct ownership of 146,403 shares of AMRX, which is worth approximately $1.7 Million. The most recent transaction as insider was on Nov 12, 2025, when has been sold 131,856 shares (Class A Common Stock) at a price of $11.92 per share, resulting in proceeds of $1,571,723. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 146K

0% 3M change

49.8% 12M change

Total Value Held $1.7 Million

Nikita Shah Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 12 2025	SELL Open market or private sale	$1,571,723 $11.92 p/Share	131,856 Reduced 47.39%	146,403 Class A Common Stock
Nov 12 2025	BUY Exercise of conversion of derivative security	$362,604 $2.75 p/Share	131,856 Added 32.15%	278,259 Class A Common Stock
Aug 25 2025	SELL Open market or private sale	$60,230 $9.5 p/Share	6,340 Reduced 4.15%	146,403 Class A Common Stock
Aug 22 2025	SELL Open market or private sale	$1,105,992 $9.66 p/Share	114,492 Reduced 42.84%	152,743 Class A Common Stock
Aug 14 2025	SELL Open market or private sale	$666,037 $9.29 p/Share	71,694 Reduced 21.15%	267,235 Class A Common Stock
Aug 12 2025	SELL Open market or private sale	$451,999 $9.04 p/Share	50,000 Reduced 12.86%	338,929 Class A Common Stock
May 16 2025	SELL Open market or private sale	$372,481 $7.58 p/Share	49,140 Reduced 11.22%	388,929 Class A Common Stock
Mar 04 2025	SELL Payment of exercise price or tax liability	$162,240 $8.84 p/Share	18,353 Reduced 4.02%	438,069 Class A Common Stock
Mar 04 2025	BUY Exercise of conversion of derivative security	-	35,879 Added 7.29%	456,422 Class A Common Stock
Mar 03 2025	SELL Payment of exercise price or tax liability	$1,017,281 $8.76 p/Share	116,128 Reduced 21.64%	420,543 Class A Common Stock
Mar 03 2025	BUY Exercise of conversion of derivative security	-	227,032 Added 31.46%	494,674 Class A Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$95,239 $8.67 p/Share	10,985 Reduced 3.43%	309,639 Class A Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	28,958 Added 8.28%	320,624 Class A Common Stock
Aug 14 2024	SELL Open market or private sale	$775,000 $7.75 p/Share	100,000 Reduced 25.53%	291,666 Class A Common Stock
Mar 03 2024	SELL Payment of exercise price or tax liability	$225,008 $5.47 p/Share	41,135 Reduced 9.5%	391,666 Class A Common Stock
Mar 03 2024	BUY Exercise of conversion of derivative security	-	82,103 Added 16.53%	414,648 Class A Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$83,040 $5.47 p/Share	15,181 Reduced 4.15%	350,698 Class A Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	28,957 Added 7.33%	365,879 Class A Common Stock
Feb 27 2024	SELL Payment of exercise price or tax liability	$106,605 $5.71 p/Share	18,670 Reduced 5.25%	336,922 Class A Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	-	35,620 Added 9.11%	355,592 Class A Common Stock
Mar 03 2023	SELL Payment of exercise price or tax liability	$34,682 $1.92 p/Share	18,064 Reduced 5.34%	319,972 Class A Common Stock
Mar 03 2023	BUY Exercise of conversion of derivative security	-	36,232 Added 9.68%	338,036 Class A Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$46,103 $2.09 p/Share	22,059 Reduced 6.81%	301,804 Class A Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	-	40,687 Added 11.36%	317,359 Class A Common Stock
Feb 27 2023	SELL Payment of exercise price or tax liability	$42,664 $2.16 p/Share	19,752 Reduced 6.52%	283,176 Class A Common Stock

Nikita Shah

Executive Vice President

Bridgewater, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AMRX shares.

Notify only if

Value

Insider Trading

Get notified when an Amneal Pharmaceuticals, Inc. insider buys or sells AMRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Amneal Pharmaceuticals, Inc.

Track Activities on AMRX

Account